---
schema_version: "secwatch.filing_event.v1"
accession: "0000784199-21-000203"
form_type: "8-K"
ticker: "AORT"
cik: "0000784199"
company_name: "ARTIVION, INC."
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T13:29:26.311666+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CryoLife Q3 revenue $72.2M (+11% YoY); net income $10.6M; non-GAAP EPS ($0.03)

## Summary
- Revenue $72.2M, up 11% GAAP and 9% constant currency vs Q3 2020.
- GAAP net income $10.6M ($0.26 EPS) vs net loss ($2.9M) year ago.
- Non-GAAP net loss ($1.2M) ($0.03 EPS) vs prior non-GAAP net income $4.9M ($0.13).
- 2021 outlook: full-year revenue $296-299M; Q4 $76.5-79.5M, pro forma constant currency growth 9.5-13.7% vs Q4 2019.
- Submitted PMAs to FDA for PerClot and PROACT Mitral; approvals expected in 2022.

## SEC filing metadata
- accession: 0000784199-21-000203
- form_type: 8-K
- ticker: AORT
- cik: 0000784199
- company_name: ARTIVION, INC.
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/784199/000078419921000203/0000784199-21-000203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/784199/000078419921000203/cry-20211104x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000784199-21-000203
- JSON: https://secwatch.observer/filing/0000784199-21-000203.json
- Plain text: https://secwatch.observer/filing/0000784199-21-000203.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.